Clinical Potential of Estrogen and Progesterone Receptor Imaging

PET Clin. 2018 Jul;13(3):415-422. doi: 10.1016/j.cpet.2018.02.005.

Abstract

Molecular imaging using 16α-[18F]fluoro-17β-estradiol (FES) and 18F-fluoro-furanyl-norprogesterone PET can assess in vivo function of steroid hormone receptors in breast cancer. These experimental agents have been tested in many single-center clinical trials and show promise to elucidate prognosis and predict endocrine therapy response. The current multicenter trial of FES-PET imaging will help bring this radiotracer closer to clinical use. There is tremendous potential for these tracers to advance drug development, enhance understanding of estrogen receptor-positive tumor biology, and personalize treatment.

Keywords: Breast cancer; Estrogen receptor imaging; FES-PET; FFNP-PET; Progesterone receptor imaging.

Publication types

  • Review

MeSH terms

  • Breast Neoplasms / diagnostic imaging*
  • Breast Neoplasms / metabolism*
  • Estradiol / analogs & derivatives
  • Female
  • Fluorodeoxyglucose F18
  • Humans
  • Positron-Emission Tomography / methods*
  • Radiopharmaceuticals*
  • Receptors, Estrogen / metabolism*
  • Receptors, Progesterone / metabolism*

Substances

  • Radiopharmaceuticals
  • Receptors, Estrogen
  • Receptors, Progesterone
  • Fluorodeoxyglucose F18
  • Estradiol
  • 16-fluoroestradiol